| 000 | 01811 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516053602.0 | ||
| 264 | 0 | _c20111020 | |
| 008 | 201110s 0 0 eng d | ||
| 022 | _a1433-6510 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSharkovska, Yuliya | |
| 245 | 0 | 0 |
_aRenoprotective effects of combined endothelin-converting enzyme/neutral endopeptidase inhibitor SLV338 in acute and chronic experimental renal damage. _h[electronic resource] |
| 260 |
_bClinical laboratory _c2011 |
||
| 300 |
_a507-15 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcute Kidney Injury _xdrug therapy |
| 650 | 0 | 4 |
_aAlbuminuria _xetiology |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAspartic Acid Endopeptidases _xantagonists & inhibitors |
| 650 | 0 | 4 | _aConstriction |
| 650 | 0 | 4 | _aDisease Models, Animal |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aEndothelin-Converting Enzymes |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 |
_aGlomerulosclerosis, Focal Segmental _xetiology |
| 650 | 0 | 4 |
_aHypertension _xchemically induced |
| 650 | 0 | 4 |
_aKidney _xblood supply |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMetalloendopeptidases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aNG-Nitroarginine Methyl Ester _xtoxicity |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 |
_aNeprilysin _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRats |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 |
_aReperfusion Injury _xcomplications |
| 700 | 1 | _aKalk, Philipp | |
| 700 | 1 | _avon Websky, Karoline | |
| 700 | 1 | _aRelle, Katharina | |
| 700 | 1 | _aPfab, Thiemo | |
| 700 | 1 | _aAlter, Markus | |
| 700 | 1 | _aFischer, Yvan | |
| 700 | 1 | _aHocher, Berthold | |
| 773 | 0 |
_tClinical laboratory _gvol. 57 _gno. 7-8 _gp. 507-15 |
|
| 999 |
_c21129708 _d21129708 |
||